Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
04 February 2009 - 11:30PM
PR Newswire (US)
JERUSALEM, Israel, February 4 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative
drug delivery systems, announced today that it has concluded a
proof of concept study in South Africa of insulin suppositories,
ORMD-0802, using its proprietary technology. Eight healthy
volunteers came for two visits, with two different formulations.
The insulin suppositories showed rapid insulin absorption and
reactive glucose lowering effect. The suppositories were well
tolerated and no adverse events were encountered. Oramed's insulin
suppositories are advanced as a treatment alternative for
injectable insulin. Such an alternative may be especially useful
for individuals with immunological-based reactions to repeated
injections and who require a temporary recess from daily
injections. Suppositories are often used in pediatrics for the
treatment of conditions such as nausea and vomiting, sedation,
analgesia, control of seizures, or antipyresis. Suppositories also
provide rapid absorption and have the advantage of being relatively
painless. "This proof of concept study of ORMD-0802, insulin
suppository, was an important milestone in using our proprietary
technology to expand our product pipeline," said Oramed's CEO,
Nadav Kidron. About Oramed Pharmaceuticals Oramed Pharmaceuticals
is a technology pioneer in the field of oral delivery solutions for
drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule
currently in phase 2 clinical trials. Established in 2006, Oramed's
technology is based on over 25 years of research by top research
scientists at Jerusalem's Hadassah Medical Center. The Company's
corporate and R&D headquarters are based in Jerusalem. For more
information, please visit http://www.oramed.com/ Forward-looking
statements Some of the statements contained in this press release
are forward-looking statements which involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry
results, to be materially different from any future results,
performance or achievements expressed or implied by such forward
looking statements, including the risks and uncertainties related
to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg USA:
+1-347-677-0042 Int'l: +972-54-566-7713 Office: +972-2-566-0001
Email: DATASOURCE: Oramed Pharmaceuticals Inc. CONTACT: Company and
Investor Relation Contacts: Oramed Pharmaceuticals, Eric Rosenberg,
USA: +1-347-677-0042, Int'l: +972-54-566-7713, Office:
+972-2-566-0001, Email:
Copyright